The association of DNA Repair with breast cancer risk in women. A comparative observational study

BMC Cancer

Jaime Matta⁸  Miguel Echenique³  Esperanza Negron⁸  Luisa Morales⁸  Wanda Vargas⁸  Felipe Sánchez Gaetan⁷  Eduardo Ramírez Lizardi¹⁰  Aníbal Torres⁹  Jose Ortiz Rosado²  Guillermo Bolaños¹²  Juan González Cruz⁷  Joaquín Laboy¹  Ricardo Barnes¹  Santos Santiago Medina⁶  Ángel Romero¹⁰  Rosendo Martinez⁷  Julie Dutil¹¹  Erick Suarez⁴  Carolina Alvarez-Garriga⁵  Manuel Bayona⁵ 

[1] Outpatient Clinics, Ponce School of Medicine and Health Sciences, Ponce, Puerto Rico

[2] Department of Surgery and Private Practice, Ponce School of Medicine and Health Sciences, Ponce, Puerto Rico

[3] Auxilio Mutuo Hospital, San Juan, Puerto Rico

[4] School of Public Health, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico

[5] Current address: Division of Epidemiology/OSB/CDRH, Food and Drug Administration, Silver Spring, Maryland, USA

[6] Dr. Pila Hospital, Ponce, Puerto Rico

[7] Department of Surgery and Damas Hospital, Ponce School of Medicine and Health Sciences, Ponce, Puerto Rico

[8] Department of Pharmacology, Physiology, and Toxicology, Department of Surgery, Ponce School of Medicine and Health Sciences, Ponce, Puerto Rico, 00732

[9] Department of Surgery, Ponce School of Medicine and Health Sciences, Ponce, Puerto Rico

[10] Private Practice, Ponce, Puerto Rico

[11] Department of Biochemistry, Ponce School of Medicine and Health Sciences, Ponce, Puerto Rico

[12] Department of Surgery and San Lucas Hospital, Ponce School of Medicine and Health Sciences, Ponce, Puerto Rico

关键词: Biomarker;    Risk;    Association;    DNA repair capacity;    Breast cancer;   

Others  :  1080120
DOI  :  10.1186/1471-2407-12-490

 received in 2011-12-06, accepted in 2012-10-15,  发布年份 2012

【 摘 要 】

Background

Previous studies have found a link between a low DNA repair capacity (DRC) level and increased cancer risk. Our aim was to assess the statistical association of DRC level and breast cancer (BC) using a case–control epidemiological study in a Hispanic community.

Methods

We conducted a comparative observational study to assess the validity of DRC in detecting BC in 824 women throughout Puerto Rico. Over a 6-year period, we compared 285 women newly diagnosed with BC to 539 without BC. DRC levels were measured in lymphocytes by means of a host-cell reactivation assay. We assessed the sensitivity, specificity, and association using the receiver operating characteristic curve analysis. Multiple logistic regression-adjusted odds ratios were estimated with 95% confidence level to measure the strength of the association of DRC and BC after adjusting for all confounders simultaneously.

Results

Compared to women without cancer, women with BC showed an average decrease of 60% in their DRC levels (p < 0.001). Validity of the association of DRC as a measure of BC risk showed a sensitivity of 83.2% and specificity of 77.6% (p < 0.0001).

Conclusions

Our results support the usefulness of DRC level as a measure of BC risk. Additional studies in other populations are needed to further verify its usefulness.

【 授权许可】

   
2012 Matta et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Ferlay J, Bray F, Pisani P, Parkin DM: GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC CancerBase No. 5. Lyon: IARCPress; 2001. Limited version available from: URL: http://globocan.iarc.fr/ webcite Last updated on 03/02/2001
• [2]Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300.
• [3]Torres-Cintron M, Ortiz AP, Perez-Irizarry J, Soto-Salgado M, Figueroa-Valles NR, De La Torre-Feliciano T, Ortiz-Ortiz KJ, Calo WA, Suarez-Perez E: Incidence and mortality of the leading cancer types in Puerto Rico: 1987–2004. P R Health Sci J 2010, 29(3):317-329.
• [4]Kelley M: Introduction and Overview of DNA Repair Targets: from Bench to Clinic. In DNA Repair in Cancer Therapy: Molecular targets and Clinical Aplications. First edition. Edited by Kelley MR. United States of America: Elsevier Inc; 2012:1-16.
• [5]Grossman L, Wei Q: DRC as a biomarker of human variational responses to the environment. In DNA Repair Mechanisms: Impact on Human Diseases and Cancer. Edited by Vos J-MH. Austin: R.G. Landes Company; 1994:329-347.
• [6]Athas WF, Hedayati MA, Matanoski GM, Farmer ER, Grossman L: Development and field-test validation of an assay for DNA repair in circulating human lymphocytes. Cancer Res 1991, 51(21):5786-5793.
• [7]Helzlsouer KJ, Harris EL, Parshad R, Perry HR, Price FM, Sanford KK: DNA repair proficiency: potential susceptiblity factor for breast cancer. J Natl Cancer Inst 1996, 88(11):754-755.
• [8]Jyothish B, Ankathil R, Chandini R, Vinodkumar B, Nayar GS, Roy DD, Madhavan J, Nair MK: DNA repair proficiency: a potential marker for identification of high risk members in breast cancer families. Cancer Lett 1998, 124(1):9-13.
• [9]Matta JL, Villa JL, Ramos JM, Sanchez J, Chompre G, Ruiz A, Grossman L: DNA repair and nonmelanoma skin cancer in Puerto Rican populations. J Am Acad Dermatol 2003, 49(3):433-439.
• [10]Patel RK, Trivedi AH, Arora DC, Bhatavdekar JM, Patel DD: DNA repair proficiency in breast cancer patients and their first-degree relatives. Int J Cancer 1997, 73(1):20-24.
• [11]Ramos JM, Ruiz A, Colen R, Lopez ID, Grossman L, Matta JL: DNA repair and breast carcinoma susceptibility in women. Cancer 2004, 100(7):1352-1357.
• [12]Wei Q, Matanoski GM, Farmer ER, Hedayati MA, Grossman L: DNA repair and aging in basal cell carcinoma: a molecular epidemiology study. Proc Natl Acad Sci USA 1993, 90(4):1614-1618.
• [13]Wei Q, Matanoski GM, Farmer ER, Hedayati MA, Grossman L: DNA repair and susceptibility to basal cell carcinoma: a case–control study. Am J Epidemiol 1994, 140(7):598-607.
• [14]Wei Q, Cheng L, Hong WK, Spitz MR: Reduced DNA repair capacity in lung cancer patients. Cancer research 1996, 56(18):4103-4107.
• [15]Wei Q, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Strom SS, Wang LE, Guo Z, Qiao Y, Amos CI, et al.: Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. J Natl Cancer Inst 2003, 95(4):308-315.
• [16]Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA: DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008, 8(3):193-204.
• [17]Hu Z, Wang L, Wei Q, Chen Q: Molecular epidemiology of DNA repair and cancer susceptibility. In DNA Repair, Genetic Instability and Cancer. Edited by Qingyi Wei Q, Lei L, David J, Chen Q. Singapore: World Scientific Publishing Co. Pte. Ltd; 2007:315-343.
• [18]Benhamou S, Sarasin A: Variability in nucleotide excision repair and cancer risk: a review. Mutat Res 2000, 462(2–3):149-158.
• [19]Murray D, Berg AC: Relationship among DNA repair genes, cellular radiosentitivity, and the response of tumors and normal tissues to radiotherapy. In DNA Repair in Cancer Therapy. Edited by Kelley MR. New York: Humana Press; 2004:211-256.
• [20]Mohrenweiser HW, Jones IM: Variation in DNA repair is a factor in cancer susceptibility: a paradigm for the promises and perils of individual and population risk estimation? Mutat Res 1998, 400(1–2):15-24.
• [21]Ramos J, Villa J, Ruiz A, Armstrong R, Matta J: UV dose determines key characteristics of nonmelanoma skin cancer. Cancer Epidemiol Biomarkers Prev 2004, 13(12):2006-2011.
• [22]Latimer JJ, Johnson JM, Kelly CM, Miles TD, Beaudry-Rodgers KA, Lalanne NA, Vogel VG, Kanbour-Shakir A, Kelley JL, Johnson RR, et al.: Nucleotide excision repair deficiency is intrinsic in sporadic stage I breast cancer. Proc Natl Acad Sci USA 2010, 107(50):21725-21730.
• [23]Kovacs E, Stucki D, Weber W, Muller H: Impaired DNA-repair synthesis in lymphocytes of breast cancer patients. Eur J Cancer Clin Oncol 1986, 22(7):863-869.
• [24]Le Scodan R, Cizeron-Clairac G, Fourme E, Meseure D, Vacher S, Spyratos F, de la Lande B, Cvitkovic F, Lidereau R, Bieche I: DNA repair gene expression and risk of locoregional relapse in breast cancer patients. Int J Radiat Oncol Biol Phys 2010, 78(2):328-336.
• [25]Xiong P, Bondy ML, Li D, Shen H, Wang LE, Singletary SE, Spitz MR, Wei Q: Sensitivity to benzo(a)pyrene diol-epoxide associated with risk of breast cancer in young women and modulation by glutathione S-transferase polymorphisms: a case–control study. Cancer Res 2001, 61(23):8465-8469.
• [26]Shi Q, Wang LE, Bondy ML, Brewster A, Singletary SE, Wei Q: Reduced DNA repair of benzo[a]pyrene diol epoxide-induced adducts and common XPD polymorphisms in breast cancer patients. Carcinogenesis 2004, 25(9):1695-1700.
• [27]Motykiewicz G, Faraglia B, Wang LW, Terry MB, Senie RT, Santella RM: Removal of benzo(a)pyrene diol epoxide (BPDE)-DNA adducts as a measure of DNA repair capacity in lymphoblastoid cell lines from sisters discordant for breast cancer. Environ Mol Mutagen 2002, 40(2):93-100.
• [28]Kennedy DO, Agrawal M, Shen J, Terry MB, Zhang FF, Senie RT, Motykiewicz G, Santella RM: DNA repair capacity of lymphoblastoid cell lines from sisters discordant for breast cancer. J Natl Cancer Inst 2005, 97(2):127-132.
• [29]Szklo M, Nieto FJ: Epidemiology: Beyond Basics. Boston: Jones and Bartlett; 2007.
• [30]Rothman KJ, S Greenland LT: Modern Epidemiology. 3rd edition. New York: Lippincott Williams & Wilkins; 2008.
• [31]van Loon AA, Timmerman AJ, van der Schans GP, Lohman PH, Baan RA: Different repair kinetics of radiation-induced DNA lesions in human and murine white blood cells. Carcinogenesis 1992, 13(3):457-462.
• [32]Leprat FAC, Rosselli F: Impaired DNA repair as assessed by the "comet" assay in patients with thyroid tumors after a history of radiation therapy: a preliminary study. Int J Radiat Oncol Biol Phys 1998, 40:1019-1026.
• [33]Bosken CH, Wei QY, Amos CI, Spitz MR: An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 2002, 94(14):1091-1099.
• [34]Hall J, English DR, Artuso M, Armstrong BK, Winter M: DNA repair capacity as a risk factor for non-melanocytic skin cancer–a molecular epidemiological study. Int J Cancer 1994, 58(2):179-184.
• [35]Spitz MR, Wu X, Wang Y, Wang LE, Shete S, Amos CI, Guo Z, Lei L, Mohrenweiser H, Wei Q: Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001, 61(4):1354-1357.
• [36]Cheng L, Eicher SA, Guo ZZ, Hong WK, Spitz MR, Wei QY: Reduced DNA repair capacity in head and neck cancer patients. Cancer Epidemiol Biomarkers Prev 1998, 7(6):465-468.
• [37]Landi MT, Baccarelli A, Tarone RE, Pesatori A, Tucker MA, Hedayati M, Grossman L: DNA repair, dysplastic nevi, and sunlight sensitivity in the development of cutaneous malignant melanoma. J Natl Cancer Inst 2002, 94(2):94-101.
• [38]Qiao Y, Spitz MR, Guo Z, Hadeyati M, Grossman L, Kraemer KH, Wei Q: Rapid assessment of repair of ultraviolet DNA damage with a modified host-cell reactivation assay using a luciferase reporter gene and correlation with polymorphisms of DNA repair genes in normal human lymphocytes. Mutat Res 2002, 509(1–2):165-174.
• [39]Rosner B: Fundamentals of Biostatistics. 6th edition. Pacific Grove (CA): Duxbury Press; 2005.
• [40]Metz CE: Basic principles of ROC analysis. Semin Nucl Med 1978, 8(4):283-298.
• [41]Zweig MH, Campbell G: Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993, 39(4):561-577.
• [42]Griner PF, Mayewski RJ, Mushlin AI, Greenland P: Selection and interpretation of diagnostic tests and procedures. Principles and applications. Ann Intern Med 1981, 94(4 Pt 2):557-592.
• [43]D'Errico M, Calcagnile A, Iavarone I, Sera F, Baliva G, Chinni LM, Corona R, Pasquini P, Dogliotti E: Factors that influence the DNA repair capacity of normal and skin cancer-affected individuals. Cancer Epidemiol Biomarkers Prev 1999, 8(6):553-559.
• [44]Wei Q, Cheng L, Amos CI, Wang LE, Guo Z, Hong WK, Spitz MR: Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 2000, 92(21):1764-1772.
• [45]Hu JJ, Hall MC, Grossman L, Hedayati M, McCullough DL, Lohman K, Case LD: Deficient nucleotide excision repair capacity enhances human prostate cancer risk. Cancer Res 2004, 64(3):1197-1201.
• [46]Powell NG, Hibbitts SJ, Boyde AM, Newcombe RG, Tristram AJ, Fiander AN: The risk of cervical cancer associated with specific types of human papillomavirus: a case–control study in a UK population. Int J Cancer 2011, 128(7):1676-1682.
• [47]Chen HC, Schiffman M, Lin CY, Pan MH, You SL, Chuang LC, Hsieh CY, Liaw KL, Hsing AW, Chen CJ: Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst 2011, 103(18):1387-1396.
• [48]Almonte M, Ferreccio C, Gonzales M, Delgado JM, Buckley CH, Luciani S, Robles SC, Winkler JL, Tsu VD, Jeronimo J, et al.: Risk factors for high-risk human papillomavirus infection and cofactors for high-grade cervical disease in Peru. Int J Gynecol Cancer 2011, 21(9):1654-1663.
• [49]Chuang LC, Hu CY, Chen HC, Lin PJ, Lee B, Lin CY, Pan MH, You SL, Hsieh CY, Chen CJ: Associations of human leukocyte antigen class II genotypes with human papillomavirus 18 infection and cervical intraepithelial neoplasia risk. Cancer 2012, 118(1):223-231.
• [50]Sinha S, Singh RK, Alam N, Roy A, Roychoudhury S, Panda CK: Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: pathological significance in early- and late-onset breast carcinoma. Mol Cancer 2008, 7:84. BioMed Central Full Text
• [51]Pooley KA, Baynes C, Driver KE, Tyrer J, Azzato EM, Pharoah PD, Easton DF, Ponder BA, Dunning AM: Common single-nucleotide polymorphisms in DNA double-strand break repair genes and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2008, 17(12):3482-3489.
• [52]Martin L, Coffey M, Lawler M, Hollywood D, Marignol L: DNA mismatch repair and the transition to hormone independence in breast and prostate cancer. Cancer Lett 2010, 291(2):142-149.